Company Profile for Trevena, Inc.
Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines. Trevena's oliceridine is in Phase 3 development for the management of moderate to severe acute pain, and is the first pain program granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.
|
Company: |
Trevena, Inc. |
||
|
Headquarters Address: |
1018 West 8th Ave, Suite A | ||
| King of Prussia, PA 19406 | |||
|
Main Telephone: |
610-354-8840 | ||
|
Website: |
|||
|
Ticker/ISIN: |
TRVN(NASDAQ)/US89532E1091 | ||
|
Type of Organization: |
Public | ||
|
Industry: |
Biotechnology | ||
|
Key Executives: |
CEO: Maxine Gowen |
||
|
Investor Relations |
|||
|
Contact: |
Jonathan Violin | ||
|
Phone: |
610-534-8840 | ||
|
Email: |
|||
View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005022/en/
Source: Trevena, Inc.
Released August 5, 2016